AU2012391490B2 - Antigens associated with inflammatory bowel disease - Google Patents

Antigens associated with inflammatory bowel disease Download PDF

Info

Publication number
AU2012391490B2
AU2012391490B2 AU2012391490A AU2012391490A AU2012391490B2 AU 2012391490 B2 AU2012391490 B2 AU 2012391490B2 AU 2012391490 A AU2012391490 A AU 2012391490A AU 2012391490 A AU2012391490 A AU 2012391490A AU 2012391490 B2 AU2012391490 B2 AU 2012391490B2
Authority
AU
Australia
Prior art keywords
amino acid
seq
domain
antibody
ibd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012391490A
Other languages
English (en)
Other versions
AU2012391490A1 (en
Inventor
Jianqing Chen
Giovanni Neri
Denise O'hara
Melanie Ruzek
Kathrin Schwager
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philogen SpA
Original Assignee
Philogen SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50435280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012391490(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Philogen SpA filed Critical Philogen SpA
Publication of AU2012391490A1 publication Critical patent/AU2012391490A1/en
Application granted granted Critical
Publication of AU2012391490B2 publication Critical patent/AU2012391490B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012391490A 2012-10-03 2012-10-03 Antigens associated with inflammatory bowel disease Active AU2012391490B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/058574 WO2014055073A1 (en) 2012-10-03 2012-10-03 Antigens associated with inflammatory bowel disease

Publications (2)

Publication Number Publication Date
AU2012391490A1 AU2012391490A1 (en) 2015-04-30
AU2012391490B2 true AU2012391490B2 (en) 2018-02-15

Family

ID=50435280

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012391490A Active AU2012391490B2 (en) 2012-10-03 2012-10-03 Antigens associated with inflammatory bowel disease

Country Status (21)

Country Link
US (2) US9695232B2 (enExample)
EP (1) EP2903629B1 (enExample)
JP (1) JP6158933B2 (enExample)
KR (1) KR102011549B1 (enExample)
CN (2) CN104768563B (enExample)
AU (1) AU2012391490B2 (enExample)
CA (1) CA2886152C (enExample)
CO (1) CO7380754A2 (enExample)
DK (1) DK2903629T3 (enExample)
ES (1) ES2743423T3 (enExample)
HU (1) HUE044927T2 (enExample)
IL (1) IL237856B (enExample)
IN (1) IN2015DN03229A (enExample)
MX (1) MX364535B (enExample)
PH (1) PH12015500662B1 (enExample)
PL (1) PL2903629T3 (enExample)
PT (1) PT2903629T (enExample)
RU (1) RU2612878C2 (enExample)
SG (1) SG11201502404WA (enExample)
SI (1) SI2903629T1 (enExample)
WO (1) WO2014055073A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2209805T (pt) 2007-10-30 2017-11-14 Philogen Spa Um antigénio associado a artrite reumatoide
SI2903629T1 (sl) 2012-10-03 2019-09-30 Philogen S.P.A. Konjugat protitelesa za uporabo pri zdravljenju vnetnih črevesnih bolezni
GB201507908D0 (en) 2015-05-08 2015-06-24 Philogen Spa IL2 and TNF immunoconjugates
US20190309060A1 (en) 2016-01-15 2019-10-10 Philogen S.P.A. Intestinal antigens for pharmacodelivery applications
CA3065153C (en) 2017-06-07 2023-09-05 Philogen S.P.A. Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
JP2022524018A (ja) * 2019-03-06 2022-04-27 デカ バイオサイエンシーズ， インコーポレイテッド Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
IL300062A (en) 2020-07-20 2023-03-01 Deka Biosciences Inc Dual fused cytokine proteins containing IL-10
WO2022018126A1 (en) 2020-07-22 2022-01-27 Philogen S.P.A. Treatment of pulmonary hypertension
US20250197485A1 (en) 2022-03-17 2025-06-19 Universitätsklinikum Jena Anti-ED-A Antibodies for the Treatment of Pulmonary Hypertension

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110250131A1 (en) * 2009-01-07 2011-10-13 Philogen S.P.A. Antigens Associated with Endometriosis, Psoriatic Arthritis and Psoriasis

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE425839C (de) 1923-08-09 1926-03-02 Optische Anstalt C P Goerz Akt Verfahren zur Erzeugung des Schleifdruckes und der Schleifrelativbewegung zwischen dem Gegenstande, dessen Oberflaeche durch Schleifen bearbeitet werden soll (Glas, Linse usw.), und der Schleifflaeche des umlaufenden Schleifwerkzeuges
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
US5420012A (en) 1989-05-08 1995-05-30 Locus Genex Oy Method for the detection of reactive conditions
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992017604A1 (fr) 1991-03-26 1992-10-15 Otsuka Pharmaceutical Factory, Inc. Anticorps monoclonal anti-eda
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5368854A (en) * 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5644033A (en) 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
PT1137941E (pt) 1998-12-10 2009-10-15 Brystol Myers Squibb Company Esqueletos de proteínas para compostos miméticos de anticorpos e outras proteínas de ligação
CA2399866C (en) 2000-02-24 2011-05-10 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
US20030152572A1 (en) 2000-04-06 2003-08-14 Yoshimi Homma Diagnostic and therapeutic agents for rheumatoid arthritis
WO2001083816A2 (en) 2000-05-04 2001-11-08 Philogen S.R.L. Method for detecting tumors
AU1218202A (en) 2000-09-07 2002-03-22 Schering Ag Receptor in the ED<sub>b</sub> fibronectin domain
US6780594B2 (en) 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
IT1317108B1 (it) 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
US20020187100A1 (en) 2000-12-21 2002-12-12 David Rizzieri Anti-tenascin monoclonal antibody therapy for lymphoma
EP1224943A1 (en) 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin as a tumor marker detected by phage antibodies
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
AU2003238284A1 (en) 2002-06-21 2004-01-06 Duke University Anti-tenascin antibody fragments and minibodies for treatment of lymphoma
EP1572131B1 (en) 2002-10-08 2016-07-06 Immunomedics, Inc. Antibody therapy
EP1572242B1 (en) 2002-12-13 2014-04-16 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US7560095B2 (en) 2003-04-22 2009-07-14 A & G Pharmaceutical, Inc. Cancer specific monoclonal antibodies
WO2005009366A2 (en) 2003-07-24 2005-02-03 Cornell Research Foundation, Inc. Restoring vascular function
US8038983B2 (en) 2003-07-29 2011-10-18 Immunomedics, Inc. Fluorinated carbohydrate conjugates
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
AU2005280528B2 (en) 2004-07-30 2010-12-23 Adeza Biomedical Corporation Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
SI1817345T1 (sl) 2004-11-09 2009-10-31 Philogen Spa Protitelesa proti tenascinu-C
KR20070102684A (ko) 2004-12-23 2007-10-19 몰메드 에스피에이 접합 생성물
CA2607954A1 (en) 2005-05-11 2006-11-16 Philogen S.P.A. Conjugate for targeting of drug
JP2009505947A (ja) 2005-06-23 2009-02-12 エモリー・ユニバーシティ 画像化剤
UA96922C2 (en) 2005-06-30 2011-12-26 Эббот Леборейториз Il-12/p40 binding protein
WO2007128557A1 (en) 2006-05-03 2007-11-15 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
JP2009536170A (ja) * 2006-05-08 2009-10-08 フィロジェン・エッセペア 治療用の抗体標的指向サイトカイン
EA018985B1 (ru) 2007-04-02 2013-12-30 Филоджен С.П.А. Новый антиген, ассоциированный с новообразованными сосудами опухолевых метастазов
JP5204228B2 (ja) 2007-07-25 2013-06-05 フィロゲン エスピーエー 腫瘍転移の新生血管と関連するフィブリノーゲンのｅｄ−ａ抗原
PT2209805T (pt) 2007-10-30 2017-11-14 Philogen Spa Um antigénio associado a artrite reumatoide
CA2748291A1 (en) 2009-01-07 2010-07-15 Philogen S.P.A. Cancer treatment
ES2712997T3 (es) 2009-08-05 2019-05-17 Philogen Spa Selección como diana de neovasculatura de médula ósea
EP2621535A1 (en) 2010-09-29 2013-08-07 Philogen S.p.A. Thiazolidine linker for the conjugation of drugs to antibodies
CA2842053C (en) 2011-07-27 2018-01-16 Philogen S.P.A. Il-12 immunoconjugate
SI2903629T1 (sl) 2012-10-03 2019-09-30 Philogen S.P.A. Konjugat protitelesa za uporabo pri zdravljenju vnetnih črevesnih bolezni
EP2988784A1 (en) 2013-04-25 2016-03-02 Philogen S.p.A. Antibody-drug conjugates
CA2910044A1 (en) 2013-04-26 2014-10-30 Philogen S.P.A. Il4 conjugated to antibodies against extracellular matrix components
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110250131A1 (en) * 2009-01-07 2011-10-13 Philogen S.P.A. Antigens Associated with Endometriosis, Psoriatic Arthritis and Psoriasis

Also Published As

Publication number Publication date
US10239939B2 (en) 2019-03-26
US20150361161A1 (en) 2015-12-17
CA2886152A1 (en) 2014-04-10
SI2903629T1 (sl) 2019-09-30
ES2743423T3 (es) 2020-02-19
RU2015115399A (ru) 2016-11-27
MX364535B (es) 2019-04-29
MX2015003908A (es) 2015-08-05
CO7380754A2 (es) 2015-09-10
PH12015500662A1 (en) 2015-05-18
AU2012391490A1 (en) 2015-04-30
PT2903629T (pt) 2019-09-10
PH12015500662B1 (en) 2019-05-31
IL237856A0 (en) 2015-05-31
SG11201502404WA (en) 2015-05-28
DK2903629T3 (da) 2019-08-05
NZ631476A (en) 2017-06-30
CN111329994A (zh) 2020-06-26
EP2903629A4 (en) 2016-07-27
KR20150061648A (ko) 2015-06-04
EP2903629B1 (en) 2019-07-10
EP2903629A1 (en) 2015-08-12
JP2016500670A (ja) 2016-01-14
JP6158933B2 (ja) 2017-07-05
HK1212220A1 (en) 2016-06-10
CN104768563B (zh) 2020-02-28
US9695232B2 (en) 2017-07-04
IN2015DN03229A (enExample) 2015-10-02
RU2612878C2 (ru) 2017-03-13
WO2014055073A1 (en) 2014-04-10
CA2886152C (en) 2020-01-14
US20180044408A1 (en) 2018-02-15
IL237856B (en) 2019-11-28
HUE044927T2 (hu) 2019-11-28
PL2903629T3 (pl) 2019-12-31
CN104768563A (zh) 2015-07-08
KR102011549B1 (ko) 2019-08-16

Similar Documents

Publication Publication Date Title
US10239939B2 (en) Anti-ED-A immunoconjugates for inflammatory bowel disease
US10112992B2 (en) Antigens associated with endometriosis, psoriatic arthritis and psoriasis
ES2807753T3 (es) Un antígeno asociado con artritis reumatoide
CA3085960C (en) Antibodies to tumour antigens
TWI499426B (zh) 與發炎性腸病有關之抗原
JP2017197558A (ja) 炎症性腸疾患に関連する抗原
HK1212220B (zh) 与炎性肠病有关的抗原
HK40023278A (en) Antigens associated with inflammatory bowel disease
NZ631476B2 (en) Antigens associated with inflammatory bowel disease
HK1191353A (en) An antigen associated with rheumatoid arthritis
HK1191353B (en) An antigen associated with rheumatoid arthritis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)